Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 22 2021 - 10:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 22 July 2021, London UK - LSE announcement
Brian McNamara appointed CEO Designate of new independent Consumer
Healthcare company
The Board of GSK (GSK) today announces that Brian McNamara, the CEO
of GSK Consumer Healthcare (a Joint Venture between GSK and Pfizer)
has been appointed as CEO Designate of the new, listed Consumer
Healthcare company which will result from the proposed demerger of
Consumer Healthcare from GSK in 2022.
As set out at GSK's Investor Update on 23 June 2021, subject to
approval from shareholders, the separation of Consumer Healthcare
will be by way of a demerger in mid-2022 of at least 80% of GSK's
holding to shareholders. The new resulting Consumer Healthcare
company is expected to attain a premium listing on the London Stock
Exchange.
The company will be a new world-leader in Consumer Health with a
portfolio which generated annual sales of more than £10
billion in 2020. The company will have a strong portfolio of brands
including Sensodyne, Voltaren,
Panadol and Centrum and will hold category leadership positions
and major sales presences in the US and China.
Sir Jonathan Symonds, GSK
Chairman, said: "We are
delighted to announce Brian's appointment to lead the proposed new
Consumer Healthcare company, following a thorough process conducted
by the Board. Brian is an exceptional leader, and through two
global integrations, has successfully transformed GSK Consumer
Healthcare into a category-leading business. His strong track
record of success and deep experience of fast moving consumer goods
and consumer health, proven at P&G, Novartis and GSK, means he
is the right choice to unlock the potential of Consumer Healthcare
as an independent company and deliver its strong prospects for
sustainable sales and profit growth, high cash generation and
attractive returns for shareholders."
Brian joined
GSK from Novartis in 2015, where he was head of the Over the
Counter (OTC) division. He has been a driving force behind two
successful Joint Ventures, first between GSK and Novartis and more
recently with Pfizer to create a new world-leading Consumer
Healthcare business.
Brian McNamara, CEO Designate,
Consumer Healthcare, said: "I am honoured to have this opportunity.
Together with the many talented people we have in our business, I
am looking forward to our exciting future as an independent
company. I am confident we are well positioned for growth, building
on our brands and innovation, with leading-edge science and human
understanding, to deliver better everyday health."
Appointment and selection process
As previously communicated, the Board of GSK conducted an extensive
search and selection process to appoint a CEO Designate for the new
Consumer Healthcare company. The process, conducted over six months
and supported by two leading global search firms, was overseen by
the Nominations & Corporate Governance Committee and resulted
in direct evaluation and interview of several external and internal
candidates for the position.
Consumer Healthcare Board
With the separation of Consumer Healthcare, the Board of GSK has
been preparing for two separate, appropriately qualified,
independent boards at the point of separation. A formal process to
appoint a Chair and to form a Board of Directors for the new
Consumer Health company is well underway. The appointment of a
Chair is expected in the second half of 2021 who will then, in
accordance with best practice, lead the process of appointments to
establish the new Board. This new Board will include the
appropriate mix of skills, experience, diversity and continuity,
relevant to Consumer Health, to represent and maximise the value of
this new business for shareholders.
Notes to Editors
Brian McNamara - additional information
Brian began his career at P&G and, over a 16-year tenure,
gained extensive experience in product supply, brand marketing, and
customer leadership before moving to Novartis in 2004.
Brian is a Board member of the Consumer Goods Forum (CGF). He
previously served as a Board Member of the Global Self Care
Federation (GSCF) for seven years, acting as Chairman from February
2017 to March 2019 and, for three years was an active member of the
Board of Trustees for Treloar's - a trust providing support and
independence education for young people with physical
disabilities.
Brian has an undergraduate degree in Electrical Engineering from
Union College in Schenectady, New York and an MBA in Finance from
University of Cincinnati.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
GSK enquiries:
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
Analyst/Investor enquiries:
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary
statement regarding forward-looking statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described in the Company's Annual Report on Form
20-F for 2020 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8 9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: July
22, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024